Cellebrite DI (NASDAQ:CLBT) CEO Thomas Hogan Sells 103,188 Shares of Stock

Cellebrite DI Ltd. (NASDAQ:CLBT) CEO Thomas Hogan sold 103,188 shares of the firm’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $15.76, for a total value of $1,626,242.88. Following the completion of the sale, the chief executive officer directly owned 590,777 shares of the company’s stock, valued at approximately $9,310,645.52. The trade was a 14.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Cellebrite DI Trading Down 0.2%

CLBT stock opened at $16.57 on Wednesday. The firm has a market capitalization of $4.13 billion, a PE ratio of 59.18, a PEG ratio of 2.06 and a beta of 1.17. Cellebrite DI Ltd. has a 1-year low of $11.02 and a 1-year high of $19.98. The business’s 50 day simple moving average is $13.56 and its 200 day simple moving average is $14.56.

Institutional Investors Weigh In On Cellebrite DI

A number of hedge funds and other institutional investors have recently modified their holdings of CLBT. Towarzystwo Funduszy Inwestycyjnych PZU SA boosted its position in shares of Cellebrite DI by 81.0% in the fourth quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company’s stock valued at $34,000 after acquiring an additional 850 shares during the period. Advisory Services Network LLC acquired a new stake in Cellebrite DI in the 3rd quarter worth about $40,000. CWM LLC boosted its holdings in Cellebrite DI by 57.0% in the 4th quarter. CWM LLC now owns 2,449 shares of the company’s stock valued at $44,000 after purchasing an additional 889 shares during the period. First Horizon Corp boosted its holdings in Cellebrite DI by 421.8% in the 4th quarter. First Horizon Corp now owns 2,891 shares of the company’s stock valued at $52,000 after purchasing an additional 2,337 shares during the period. Finally, Vestcor Inc acquired a new position in shares of Cellebrite DI during the 3rd quarter worth approximately $70,000. Institutional investors and hedge funds own 45.88% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently weighed in on CLBT. Weiss Ratings raised shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 18th. DA Davidson initiated coverage on shares of Cellebrite DI in a research note on Wednesday, May 27th. They issued a “buy” rating and a $20.00 price target on the stock. Needham & Company LLC lowered their price target on shares of Cellebrite DI from $18.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, May 15th. Finally, Wall Street Zen upgraded shares of Cellebrite DI from a “sell” rating to a “hold” rating in a research report on Sunday, March 15th. Five analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $21.40.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.